Why the Mach7 (ASX:M7T) share price is roaring 6% higher today

Mach7's revenues are set for a much welcomed boost.

| More on:
two doctors smile as they sit together at a desk looking at a patient's Xray.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mach7 Technologies Ltd (ASX: M7T) share price is pushing firmly into positive territory on Tuesday. This comes after the healthcare imaging platform provider announced new sales to an existing client.

At the time of writing, Mach7 shares are up 6.53% to a 2-month high of $1.06.

Mach7 secures purchase orders

While the All Ordinaries Index (ASX: XAO) has fallen 0.63% to 7,338 points, the Mach7 share price has headed north.

According to its announcement, Mach7 advised it has received purchase orders from Trinity Health for an array of its products. These include Mach7 Enterprise Imaging Platform, eUnity Diagnostic Viewer, eUnity Enterprise Viewer, and Mach7 Universal Worklist.

Based in Michigan, Trinity Health is one of the largest multi-institutional Catholic health care delivery systems in the United States. The company services 92 hospitals, as well as 100 continuing care locations that provide care programs and senior living facilities for the elderly.

Mach7 noted the initial purchase orders have a combined value of $3.6 million for software and services. The revenues are expected to be recognised in the current financial year.

In addition, following software deployment, the orders will contribute another $3.8 million in support fees over the next 7 years. In total, this brings the initial contract value to $7.4 million for Mach7.

Mach7 CEO Mike Lampron commented:

I am excited for the opportunity to [partner] with Trinity Health, one of the top healthcare delivery networks in the United States.

I believe the full Mach7 solution is well-positioned to deliver on the strategic objectives of Trinity's Unified Clinical Imaging Platform Strategy and I look forward to being a part of their initiative.

About the Mach7 share price

Over the past 12 months, Mach7 shares have moved sideways to register a 5% loss for the period. Year-to-date also hasn't been great for investors with the company's shares down more than 15% despite today's gain.

Based on the current share price, Mach7 commands a market capitalisation of roughly $251 million with 236.8 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended MACH7 FPO. The Motley Fool Australia has recommended MACH7 FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

1 ASX stock to consider buying that could be the next ResMed

There are obviously no guarantees in the share market. But if you're willing to take on some risk, the rewards…

Read more »

A couple stares at the tv in shock, one holding the remote up ready to press.
Healthcare Shares

Why this ASX biotech stock could rise a massive 40%

Bell Potter sees big returns on the cards for investors from this speculative stock.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords share is surging 16% after announcing a new finance chief

Is this announcement the real reason for the rise?

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

GLP-1 obesity medicines do the opposite of what ResMed stock investors feared

Internal research from ResMed provides some surprising news for investors on the impact of GLP-1s.

Read more »

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
Healthcare Shares

Guess which ASX AI stock rocketed 170% on an AstraZeneca update

Investors are loving this company's announcement on Wednesday.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Guess which ASX All Ords company is being sued by shareholders over stock price losses

Some of this biotech's shareholders aren't happy with management.

Read more »